Rapid achievement of low disease activity during the use of a type I interferon inhibitor in a patient with torpid systemic lupus erythematosus (case report)
This article describes the experience of using the type I interferon inhibitor anifrolumab (AFM) in a patient with a torpid course of systemic lupus erythematosus. The reason for prescribing AFM was the need for a quick achievement of low disease activity due to a planned hip replacement. Dynamic ob...
Saved in:
Main Authors: | A. A. Baranov, E. A. Aseeva, S. K. Soloviev, N. Yu. Nikishina, E. A. Malygina, T. O. Abissova, Z. Yu. Pimenova, T. M. Reshetnyak, S. A. Makarov, N. A. Lapkina, A. M. Lila |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2024-06-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/1591 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Portrait of a patient with systemic lupus erythematosus for the prescription of the type I interferon inhibitor anifrolumab
by: T. M. Reshetnyak, et al.
Published: (2023-12-01) -
Efficacy and safety of the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus (results of a 6-month study)
by: T. M. Reshetnyak, et al.
Published: (2024-04-01) -
Experience with type I interferon inhibitor in systemic lupus erythematosus
by: Ya. A. Leineman, et al.
Published: (2022-08-01) -
New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor)
by: E. L. Nasonov, et al.
Published: (2021-10-01) -
Position on the use of anifrolumab in patients with systemic lupus erythematosus with insufficient efficacy of standard therapy in real-life clinical practice. Comments from Russian experts
by: E. A. Aseeva, et al.
Published: (2024-06-01)